The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT).
Anthony T. C. Chan
No relevant relationships to disclose
Roger K.C. Ngan
No relevant relationships to disclose
Edwin Pun Hui
No relevant relationships to disclose
Sing Fai Leung
No relevant relationships to disclose
Patricia Poon
No relevant relationships to disclose
VC Sin
No relevant relationships to disclose
Stewart Yuk Tung
No relevant relationships to disclose
Ashley Chi Kin Cheng
No relevant relationships to disclose
Tsz Kok Yau
No relevant relationships to disclose
Victor Lee
No relevant relationships to disclose
Brigette Ma
No relevant relationships to disclose
HC Cheng
No relevant relationships to disclose
Kwok Keung Yuen
No relevant relationships to disclose
Conrad Lee
No relevant relationships to disclose
Michael K. Kam
No relevant relationships to disclose
Stephen Yau
No relevant relationships to disclose
Alice Wan-ying Ng
No relevant relationships to disclose
Frankie Mo
No relevant relationships to disclose
Benny C.Y. Zee
No relevant relationships to disclose
Dennis YM Lo
No relevant relationships to disclose